Navigation Links
Genomic Health Announces Positive Topline Results of Large Prostate Cancer Clinical Validation Study; Company to Proceed with 2013 Commercial Launch
Date:9/18/2012

REDWOOD CITY, Calif., Sept. 18, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results from a large clinical validation study of its biopsy-based prostate cancer test.  The study, performed in collaboration with leading prostate cancer researchers at the University of California, San Francisco (UCSF), met its primary endpoint by demonstrating that the multi-gene Oncotype DX® Genomic Prostate Score (GPS), assessed in prostate needle biopsy tumor tissue, has been prospectively validated as a predictor of adverse pathology for patients with early-stage prostate cancer.  UCSF and Genomic Health plan to submit complete data from this study for presentation at the 2013 ASCO Genitourinary Cancers Symposium in February.  Based on these results, Genomic Health is completing the necessary work in its Clinical Reference Laboratory to make the Oncotype DX prostate cancer test available to physicians and patients in the first half of 2013.

"It is widely recognized that a very large percentage of men with low and intermediate risk prostate cancer are over-treated due in part to the lack of a standardized, validated biopsy-based test to more accurately distinguish between aggressive and clinically indolent disease," said Peter Carroll, M.D., M.P.H., Chair, Department of Urology, University of California, San Francisco. "These results have the potential to change medical practice significantly by providing physicians and their patients with a multi-gene prostate cancer test, designed specifically for biopsies, that will improve treatment decisions for early-stage prostate cancer at the time of diagnosis."

As was the case for the established Oncotype DX breast and colon cancer tests, Genomic Health and its collaborators used a rigorous clinical development strategy for development and validation of the Onc
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
2. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
3. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
4. Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook
5. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
6. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
7. Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing
8. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
9. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
10. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
11. Webinar Announcement: GenomeSpace: A New Solution for Integrating Genomic Analysis Tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... for judgment notwithstanding the verdict, a new trial, and ...
(Date:2/26/2015)... , Feb. 26, 2015   Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... Ph.D., President and Chief Executive Officer of Regulus, will ... 35 th Annual Healthcare Conference on Wednesday, March ... being held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... motions for judgment notwithstanding the verdict, a new trial, ...
(Date:2/26/2015)... 26, 2015 The Pittcon 2015 ... the Ernest N. Morial Convention Center in New ... of February 19, 2015) displaying products and services ... and government labs. The Exposition will offer the ... limited to, analytical chemistry; drug discovery; nanotechnology; life ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Pittcon 2015 Announces Exposition Highlights 2
... For the second year in a row, BioTrends Research ... companies in the Philadelphia region by the Philadelphia 100, a joint ... of Greater Philadelphia, and the Philadelphia Business Journal. , ... become an established player in the field of syndicated market research ...
... , , SEATTLE, Sept. 8 ... today that executives will present a corporate update at the ... Peter Thompson, M.D., FACP, president, chief executive officer and chairman ... president and chief financial officer, are scheduled to present on ...
... - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ... the Rodman Renshaw 11th Annual Healthcare Conference on ... will be held at the New York Palace Hotel from ... of the presentation will be available at: http://www.wsw.com/webcast/rrshq15/oncy ...
Cached Biology Technology:BioTrends Research Group is Recognized by the Philly 100 for the Second Consecutive Year 2Trubion Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference 2
(Date:2/24/2015)... report analyzes the worldwide markets for Face and Voice Biometrics in ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Middle East ... Latin America . Annual estimates and forecasts are provided for ... provided for these markets. Market data and analytics are derived from ...
(Date:2/18/2015)... 18, 2015  Cepheid (NASDAQ: CPHD ) today ... conferences, and invited investors to participate via webcast. , ... Tuesday, March 3, 2015 at 11.20 a.m. Eastern ... Orlando, FL Wednesday, March 4, 2015 at 10.25 ... the live webcasts for these events, please visit Cepheid,s website ...
(Date:2/11/2015)... According to a ... Product (Cards and Readers, Biometrics, Controllers, Management Software), ... Healthcare, Education) and By Geography - Global Forecast and Analysis to ... Control Market is expected to reach $10.4 ... of 10.6% between 2014 and 2020. ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... in the abundance of fish, shellfish, and other aquatic fauna ... in the sea: historical records show that species in rivers ... of these declines in freshwater species is frequently overlooked by ... 2009 issue of BioScience . , Authors Paul Humphries ...
... to any process by which a cell converts one ... of signal transduction involve ordered sequences of biochemical reactions ... and activated by second messengers, resulting in a signal ... the order of milliseconds in the case of ion ...
... of French scientists have found the dose of DHA (docosahexaenoic ... healthy men. In a research report appearing in the September ... http://www.fasebj.org ), the scientists show that a 200 mg dose ... that reliably predict cardiovascular problems, such as those related to ...
Cached Biology News:Shifting baselines confound river restoration 2
Recombinant Rat CINC-2 alpha, CF...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SGG (Sheep gamma globulin) lysine through amide bonds. This product is homologous to NP-BSA....
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: